Free Trial

PhenixFIN (PFX) Competitors

PhenixFIN logo
$46.68 -2.30 (-4.70%)
(As of 11/20/2024 ET)

PFX vs. HQL, TWN, SAR, MIY, ASG, MHN, TPVG, MIN, IIF, and AEF

Should you be buying PhenixFIN stock or one of its competitors? The main competitors of PhenixFIN include Abrdn Life Sciences Investors (HQL), The Taiwan Fund (TWN), Saratoga Investment (SAR), BlackRock MuniYield Michigan Quality Fund (MIY), Liberty All-Star Growth Fund (ASG), BlackRock MuniHoldings New York Quality Fund (MHN), TriplePoint Venture Growth BDC (TPVG), MFS Intermediate Income Trust (MIN), Morgan Stanley India Investment Fund (IIF), and Abrdn Emerging Markets Equity Income Fund (AEF). These companies are all part of the "financial services" industry.

PhenixFIN vs.

Abrdn Life Sciences Investors (NYSE:HQL) and PhenixFIN (NYSE:PFX) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings.

Abrdn Life Sciences Investors received 35 more outperform votes than PhenixFIN when rated by MarketBeat users. Likewise, 68.35% of users gave Abrdn Life Sciences Investors an outperform vote while only 60.61% of users gave PhenixFIN an outperform vote.

CompanyUnderperformOutperform
Abrdn Life Sciences InvestorsOutperform Votes
95
68.35%
Underperform Votes
44
31.65%
PhenixFINOutperform Votes
60
60.61%
Underperform Votes
39
39.39%

In the previous week, PhenixFIN had 1 more articles in the media than Abrdn Life Sciences Investors. MarketBeat recorded 1 mentions for PhenixFIN and 0 mentions for Abrdn Life Sciences Investors. Abrdn Life Sciences Investors' average media sentiment score of 2.00 beat PhenixFIN's score of 0.67 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the media.

Company Overall Sentiment
Abrdn Life Sciences Investors Very Positive
PhenixFIN Positive

Abrdn Life Sciences Investors has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, PhenixFIN has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 43.4% of PhenixFIN shares are held by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are held by insiders. Comparatively, 22.4% of PhenixFIN shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PhenixFIN has a net margin of 89.07% compared to Abrdn Life Sciences Investors' net margin of 0.00%. PhenixFIN's return on equity of 4.05% beat Abrdn Life Sciences Investors' return on equity.

Company Net Margins Return on Equity Return on Assets
Abrdn Life Sciences InvestorsN/A N/A N/A
PhenixFIN 89.07%4.05%2.52%

PhenixFIN has higher revenue and earnings than Abrdn Life Sciences Investors.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abrdn Life Sciences InvestorsN/AN/AN/AN/AN/A
PhenixFIN$20.13M4.68$26.92M$9.634.85

Summary

PhenixFIN beats Abrdn Life Sciences Investors on 8 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFX vs. The Competition

MetricPhenixFIN IndustryFinance SectorNYSE Exchange
Market Cap$94.29M$2.09B$10.57B$19.87B
Dividend YieldN/A15.00%10.17%3.53%
P/E Ratio4.8510.7149.3442.94
Price / Sales3.18144.373,455.5418.99
Price / Cash17.1415.4830.5017.86
Price / Book0.661.592.765.52
Net Income$26.92M$70.32M$995.76M$986.45M
7 Day Performance1.37%1.01%-0.05%0.45%
1 Month Performance-2.40%0.74%7.27%1.05%
1 Year Performance24.55%14.93%24.63%24.67%

PhenixFIN Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFX
PhenixFIN
N/A$46.68
-4.7%
N/A+24.5%$94.29M$20.13M4.857Gap Down
HQL
Abrdn Life Sciences Investors
N/A$13.79
-3.6%
N/A+17.4%$377.16MN/A0.00N/APositive News
TWN
The Taiwan Fund
N/A$42.13
-2.1%
N/A+34.4%$358.53MN/A0.00N/A
SAR
Saratoga Investment
2.027 of 5 stars
$25.73
+0.4%
$25.42
-1.2%
+0.2%$355.07M$143.72M16.753,211
MIY
BlackRock MuniYield Michigan Quality Fund
N/A$11.63
+0.2%
N/A+8.7%$341.46MN/A0.00N/A
ASG
Liberty All-Star Growth Fund
N/A$5.72
+0.7%
N/A+14.7%$333.13MN/A0.00N/APositive News
MHN
BlackRock MuniHoldings New York Quality Fund
N/A$10.65
+0.1%
N/A+8.1%$322.06MN/A0.00N/A
TPVG
TriplePoint Venture Growth BDC
1.6447 of 5 stars
$7.96
+0.1%
$7.85
-1.4%
-24.0%$318.79M$24.23M37.88N/AAnalyst Forecast
Positive News
MIN
MFS Intermediate Income Trust
N/A$2.67
flat
N/A+0.2%$303.28MN/A0.00N/AHigh Trading Volume
IIF
Morgan Stanley India Investment Fund
N/A$27.45
-0.7%
N/A+23.4%$268.74MN/A0.00N/A
AEF
Abrdn Emerging Markets Equity Income Fund
N/A$5.22
flat
N/A+5.0%$264.92MN/A0.00N/APositive News

Related Companies and Tools


This page (NYSE:PFX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners